Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Intra arterial chemotherapy
What intra arterial chemotherapy is, how catheter-directed drug delivery targets tumours directly, what the medical evidence shows for liver and eye cancers, how it compares with systemic chemotherapy and chemoembolisation, approximate costs in Turkey compared with the UK, US and Germany, recovery milestones, documented risks, and how to evaluate an oncology centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Intra Arterial Chemotherapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Intra arterial chemotherapy: what it is and how it works
Intra arterial chemotherapy (IAC) is a targeted cancer treatment delivering concentrated cytotoxic medication directly into the artery supplying a tumour. Instead of infusing chemotherapy intravenously to circulate throughout the body, an interventional radiologist guides a thin microcatheter through the vascular system—usually from the groin or wrist—directly into the tumour-feeding vessels. This regional approach provides higher drug levels at the tumour site while lowering systemic exposure in healthy tissues.
The technique is used primarily for cancers confined to specific organs, notably liver tumours and paediatric retinoblastoma in the eye. In the liver, tumours derive most blood from the hepatic artery, whereas healthy liver tissue relies mainly on the portal vein. This guide explains how the treatment works, clinical evidence, recovery, risks, and approximate costs in Turkey compared with the UK, US, and Germany. For broader oncology options, see our guide to oncology treatments in Turkey.
How does the intra arterial chemotherapy procedure work?
An intra arterial chemotherapy procedure takes place in an interventional radiology suite using real-time fluoroscopic imaging. The medical team first performs angiographic mapping by injecting contrast dye to identify the precise vessels nourishing the tumour and check for collateral branches, which may be coiled to protect adjacent organs.
The procedure follows four key stages:
- Arterial access: Under local anaesthesia and sedation (or general anaesthesia in children), a sheath is inserted into the femoral or radial artery.
- Catheter positioning: Guided by X-ray, the specialist steers a microcatheter into the tumour-feeding arterial branches.
- Medication infusion: Chemotherapy drugs—such as melphalan for retinoblastoma, or oxaliplatin-based regimens for liver tumours—are infused steadily through a precision pump over 30 to 120 minutes.
- Closure: The catheter is removed, and compression or a vascular closure device is applied to the puncture site.
A typical session takes one to two hours.
Does intra arterial chemotherapy work, and what does the clinical evidence show?
Clinical evidence confirms that intra arterial chemotherapy is effective for specific indications, though it is not suitable for every cancer. Guidelines from oncology bodies such as ESMO and NCCN recognise regional arterial chemotherapy mainly for localised liver tumours and retinoblastoma.
In paediatric retinoblastoma, ophthalmic artery infusion achieves eye-salvage rates between 70% and 85% in advanced cases, preserving vision and avoiding surgical removal of the eye. For advanced liver tumours—including colorectal liver metastases and hepatocellular carcinoma—hepatic arterial infusion chemotherapy (HAIC) produces local tumour shrinkage in 30% to 50% of selected patients in clinical trials, occasionally downstaging tumours enough for surgical resection or ablation.
However, the therapy has clear limitations. It treats only tissue supplied by the infused artery and does not address distant metastases in the lungs, bones, or lymph nodes. It is rarely curative alone in advanced stages and is usually paired with other oncological treatments.
Intra arterial chemotherapy cost in Turkey compared with the UK, US and Germany
The intra arterial chemotherapy cost depends on tumour location, the drug regimen, whether an implantable port is required, and hospital stay duration. The table below presents approximate cost ranges per cycle across four countries as broad market estimates rather than fixed hospital quotes.
| Country | Approximate cost range per cycle |
|---|---|
| Turkey | €3,000 – €8,500 |
| United Kingdom | €7,500 – €18,000 |
| United States | €12,000 – €35,000 |
| Germany | €6,500 – €16,000 |
Key factors influencing the intra arterial chemotherapy price include diagnostic imaging (CT, MRI, angiography), pharmaceutical costs, catheterisation suite time, and inpatient observation. In Turkey, an all-inclusive medical travel package generally includes pre-procedure tests, radiology fees, chemotherapy medications for the cycle, one to two nights of hospital accommodation, and airport transfers.
Intra-arterial chemotherapy compared with systemic chemotherapy and chemoembolisation
Selecting an oncological approach requires comparing intra-arterial delivery with related modalities, including intravenous systemic chemotherapy and transarterial chemoembolisation (TACE).
| Treatment approach | Best suited to | Typical limits |
|---|---|---|
| Intra-arterial chemotherapy (IAC) | Tumours confined to one vascular territory (such as liver metastases or retinoblastoma) requiring concentrated regional drug doses | Requires microcatheter arterial cannulation; does not treat cancer cells beyond the targeted arterial bed |
| Systemic chemotherapy | Cancers with systemic spread, lymph node involvement, or high risk of distant micrometastases | Circulates throughout whole body; causes broader systemic side effects and lower concentration in hypovascular tumours |
| Transarterial chemoembolisation (TACE) | Intermediate unresectable hepatocellular carcinoma with adequate hepatic arterial blood flow | Blocks feeding arteries with embolic particles; causes post-embolisation syndrome and requires good baseline liver function |
Unlike chemoembolisation, intra-arterial chemotherapy does not deliberately obstruct feeding vessels with particles. Preserving arterial blood flow allows repeated cycles through the same pathway. For comprehensive treatment, oncologists frequently combine regional infusions with systemic targeted therapy or immunotherapy to address microscopic disease elsewhere.
Which cancers and tumours can be treated?
Intra-arterial chemotherapy requires an anatomically distinct organ with identifiable arterial branches. Main clinical uses include:
- Colorectal liver metastases: When bowel cancer spreads primarily to the liver, hepatic infusion delivers concentrated medication directly into liver tissue where up to 90% is cleared during first pass, sparing other organs.
- Hepatocellular carcinoma (HCC): In primary liver cancer where portal vein involvement rules out standard surgery or chemoembolisation, regional infusion provides meaningful local tumour control.
- Paediatric retinoblastoma: Ophthalmic artery chemotherapy delivers micro-doses directly to retinal tumours in children, preserving vision and avoiding eye removal.
- Head and neck cancers: Selected advanced head and neck carcinomas can be treated via carotid branches alongside systemic neutralising agents.
- Intrahepatic cholangiocarcinoma: Unresectable bile duct cancers within the liver can be managed with arterial infusion protocols to slow local tumour progression.
Who is an appropriate candidate, and who is not?
Candidate suitability is assessed by a multidisciplinary tumour board. Favourable candidates typically present with:
- Disease primarily confined to the target organ, where local tumour control directly influences outcome or symptom relief.
- Preserved organ function, including adequate liver reserve (Child-Pugh class A or early B) and normal kidney function to eliminate contrast dye.
- Accessible arterial anatomy free from severe vascular disease or unmanageable vessel tortuosity.
- Adequate general health (ECOG score 0 to 2) to undergo catheterisation and recovery safely.
Conversely, patients are generally unsuitable if they have extensive metastases across multiple distant organs, decompensated liver failure with ascites or encephalopathy, complete blockage of major vascular access vessels, or severe uncorrected clotting abnormalities.
Treatment results and scan responses: what to expect
Evaluating progress after intra-arterial chemotherapy relies on structured imaging schedules rather than immediate physical changes. Scans are usually scheduled every two to three cycles (every six to eight weeks) using dynamic multiphase contrast CT or MRI.
For liver tumours, responses are evaluated using modified RECIST (mRECIST) criteria, which assess viable tumour tissue rather than total lesion diameter alone. A responding tumour often shows marked loss of internal arterial enhancement and central necrosis, even if its outline remains visible. Serum tumour markers, such as AFP for primary liver cancer or CEA for colorectal metastases, are tracked concurrently.
Realistic expectations are essential. Regional chemotherapy can shrink tumours and stabilise local disease, occasionally converting inoperable lesions into candidates for surgery. However, in advanced disease, its role is disease control and symptom stabilisation rather than a definitive cure.
Your medical trip to Turkey and intra arterial chemotherapy recovery
Patients travelling for intra arterial chemotherapy in Turkey generally need a stay of 5 to 7 days per treatment cycle. This schedule provides time for pre-treatment assessments, the catheterisation procedure, and post-infusion observation before flying home.
The typical timeline for intra arterial chemotherapy recovery and care includes:
- Day 1: Initial consultation, medical history review, and baseline blood tests (blood counts, liver and kidney panels, clotting screen).
- Day 2: Diagnostic scans and angiographic mapping to confirm vascular pathways.
- Day 3: Catheterisation and drug infusion in the radiology suite. Afterwards, the patient rests flat in bed for four to six hours to ensure the puncture seals, with an overnight hospital stay for monitoring.
- Days 4–5: Follow-up blood checks and wound examination. Once stable, the patient is discharged to their hotel.
- Days 6–7: Final clinical evaluation, review of aftercare guidance, and flight clearance.
Most patients experience mild fatigue for several days following a cycle, returning to everyday routines within one to two weeks. Multi-cycle regimens are typically repeated at three- to four-week intervals.
Documented risks, side effects and safety considerations
Intra-arterial chemotherapy involves both vascular catheterisation risks and pharmacological side effects. Recognised guidance from organisations like the NHS, ESMO, and ASCO highlights key safety considerations:
- Vascular access risks: Puncturing the femoral or radial artery can cause localized bruising, haematoma, arterial spasm, or rarely pseudoaneurysm formation or vessel dissection.
- Non-target drug delivery: If chemotherapy enters unintended arterial branches, it can cause severe tissue inflammation, such as stomach ulcers or gallbladder irritation. In eye infusions, temporary eyelid swelling or periocular redness can occur.
- Liver and biliary irritation: High local drug concentration in hepatic vessels can cause temporary liver enzyme elevations or chemical inflammation of the bile ducts.
- Systemic side effects: Although systemic toxicities are lower than with intravenous chemotherapy, mild nausea, temporary fatigue, and modest drops in blood counts can occur. Severe hair loss is uncommon.
Detailed angiographic mapping and continuous fluoroscopic monitoring during infusion help protect against misdirected drug delivery.
How to choose an oncology centre in Turkey, red flags and questions to ask
Selecting a hospital for intra arterial chemotherapy Turkey requires verifying specialist qualifications and clinical infrastructure. The hospital should hold accreditation from the Turkish Ministry of Health and international organisations such as JCI, featuring modern angiography suites and an on-site intensive care unit.
Be alert to red flags, including promises of guaranteed cures, willingness to treat without reviewing recent imaging and biopsy reports, absence of dedicated interventional radiologists, and vague quotes that omit hospital stay or complication costs.
Key questions to ask the oncology team include:
- Is my treatment plan reviewed by a formal multidisciplinary tumour board?
- How many intra-arterial procedures does your team perform annually?
- Which specific drugs will be used, and what response is expected?
- What intensive care facilities are available on-site if complications occur?
- What does the package price cover, and what happens if extra hospital days are needed?
- How will my treatment records be shared with my doctor at home?
To understand the coordination process, see how our coordination works. When you are ready for a clinical assessment, submit your records through our free quote form to receive a personalised treatment plan and cost estimate.
Hospitals with Oncology in Turkey
Frequently asked questions
Intra-arterial chemotherapy is a targeted cancer treatment where cytotoxic drugs are delivered directly into the artery supplying a tumour via a fine microcatheter. This regional technique produces high drug concentrations inside tumour tissue while significantly reducing circulating medication levels throughout the rest of the body.
Yes, for specific indications. It has proven effectiveness in treating paediatric retinoblastoma, where it achieves eye-salvage rates of 70% to 85%, and in managing unresectable liver tumours. However, it treats only the arterial territory infused and is rarely curative on its own in advanced metastatic disease.
Approximate costs in Turkey range from €3,000 to €8,500 per cycle, compared with €7,500 to €18,000 in the UK and €12,000 to €35,000 in the US. The price depends on diagnostic imaging, drug selection, catheterisation complexity, and hospital stay duration. A written quotation confirms exact costs.
Scans typically show reduction in active, blood-supplied tumour tissue rather than complete disappearance of the lesion. Under modified RECIST criteria, successful response is indicated by the loss of arterial enhancement and central necrosis within the tumour, alongside reductions in circulating tumour markers such as AFP or CEA.
Systemic chemotherapy is infused into a peripheral vein and circulates throughout the entire bloodstream, affecting healthy organs and causing widespread side effects. Intra-arterial chemotherapy delivers concentrated drugs directly into the tumour-feeding artery via catheterisation, achieving higher local tumour exposure with fewer whole-body toxicities.
Most patients recover from the catheter puncture within 24 to 48 hours and resume light daily activities within three to five days. Mild fatigue and appetite changes may persist for one to two weeks. In multi-cycle protocols, treatments are typically scheduled three to four weeks apart.
The catheterisation is performed under local anaesthesia with sedation or general anaesthesia, so you feel minimal discomfort during the procedure. Afterwards, patients may experience mild soreness or bruising at the groin or wrist puncture site, easily managed with standard oral painkillers.
Potential risks include arterial puncture complications such as bruising or haematoma, non-target drug delivery causing stomach or gallbladder irritation, temporary liver enzyme elevations, and mild drops in blood cell counts. Careful pre-procedure angiographic mapping and continuous X-ray monitoring minimise these complications.
Duration of benefit depends on cancer type, staging, and overall disease biology. In responsive liver tumours, disease control can last several months to years, particularly when combined with systemic therapies. In retinoblastoma, successful tumour eradication can provide durable, long-term disease control.
Patients generally need to stay 5 to 7 days in Turkey per cycle. This duration allows for pre-procedure blood tests and imaging, the catheterisation session, 24 to 48 hours of inpatient observation, and follow-up clinical checks before flying home safely.
Patient stories